TDO2 and glioblastoma: The results of the wound migration assay are consistent with the idea that the inhibition of TDO has a more pronounced impact on GBM cell motility than treatment with BCNU (at least under the conditions reported here) and that this effect can be potentiated with the co-treatment of BCNU and 680C91.